Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yidu TechFRA:0EL -0.40%72 EV-to-EBIT is 24.64 as of Aug. 12, 2026. GuruFocus rates FRA:0EL with a GF Score™ of 72/100 and a GF Value™ of €0.67 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 473 Healthcare Providers & Services companies, Yidu Tech ranks worse than 71.46% on this metric.
The historical rank and industry rank for Yidu Tech's EV-to-EBIT or its related term are showing as below:
FRA:0EL'
s EV-to-EBIT Range Over the Past 10 Years
Min: -29.53 Med: -2.31 Max: 46.04
Current: 24.71
During the past 9 years, the highest EV-to-EBIT of Yidu Tech was 46.04. The lowest was -29.53. And the median was -2.31.
FRA:0EL's EV-to-EBIT is ranked worse than 71.46% of 473
companies
in the Healthcare Providers & Services industry
Industry Median: 15.84
vs FRA:0EL: 24.71
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Yidu Tech's Enterprise Value for the quarter that ended in Mar. 2026 was €293.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Yidu Tech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €10.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yidu Tech EV-to-EBIT Related Terms
Yidu Tech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Yidu Tech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Yidu Tech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yidu Tech EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Yidu Tech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Yidu Tech's EV-to-EBIT falls into.
Yidu Tech's current Enterprise Value is €267.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Yidu Tech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €10.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yidu Tech (FRA:0EL) has a EV-to-EBIT of 24.64 as of Aug. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Yidu Tech and its competitors. According to the industry distribution chart, Yidu Tech ranks #338 out of 473 companies in the Healthcare Providers & Services industry, placing it in the top 71.5%.
Is Yidu Tech's EV-to-EBIT too high?
Yidu Tech's current EV-to-EBIT is 24.64. The Healthcare Providers & Services industry median EV-to-EBIT is 15.84. Yidu Tech's value of 24.64 is 55.6% above this industry median. Based on the distribution chart, Yidu Tech ranks #338 out of 473 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Yidu Tech has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Yidu Tech's EV-to-EBIT compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Yidu Tech ranks #338 out of 473 companies for EV-to-EBIT. This places Yidu Tech in the lower half of its industry. The industry median EV-to-EBIT is 15.84. Yidu Tech's value of 24.64 is 55.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.84, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yidu Tech's current EV-to-EBIT of 24.64 is 55.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Yidu Tech and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yidu Tech's current EV-to-EBIT is 24.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yidu Tech stock overvalued right now?
Based on GuruFocus' analysis, Yidu Tech (FRA:0EL) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.67, compared to a current price of €0.50 — trading 25.7% below its estimated fair value. The current EV-to-EBIT is 24.64 and 55.6% above the Healthcare Providers & Services industry median of 15.84. Yidu Tech's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Yidu Tech (FRA:0EL), the current EV-to-EBIT is 24.64 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yidu Tech (FRA:0EL) Overvalued in 2026?
Based on GuruFocus' analysis, Yidu Tech stock appears to be undervalued.
The current stock price of €0.50 is trading 25.7% below its estimated GF Value™ of €0.67.
GuruFocus considers Yidu Tech to be Modestly Undervalued.
Key valuation signals for FRA:0EL:
EV-to-EBIT: 24.64
GF Value™: €0.67 vs. price of €0.50 (25.7% below fair value)
Industry Position: 55.6% above the Healthcare Providers & Services median (#338 of 473)
No single metric tells the full story. See the FRA:0EL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yidu Tech Inc offers healthcare solutions built on big data and artificial intelligence (AI) technologies. The company serves various healthcare industry participants, including hospitals, pharmaceutical, biotech, research institutions, insurance companies, etc. Its operating segments are: Big data platform and solutions, Life sciences solutions, and Health management platform and solutions. The majority of the company's revenue is generated from its Big data platform and solutions segment, which provides data intelligence platforms and data analytics-driven solutions (such as Eywa 5.0, Lingxi Intelligent Management, AI Middleware, etc.) for hospitals, healthcare institutions, regulators, and policymakers. Geographically, the company generates maximum revenue from Mainland China.
72GF Score
Get the complete analysis for FRA:0EL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0EL has been successfully added to your 
